Related Experiment Videos
Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical
J Carvalho de Sousa1, E Bruckert, P Giral
1Hôpital Lariboisière, Service d'Hématologie, Paris, France.
Insights
Increased coagulation factor VII (FVII) levels correlate with triglycerides in type IV hyperlipidemia, suggesting a link between lipid profiles and thrombosis risk factors. Further research is needed to understand this relationship.
Area of Science:
- Cardiovascular Science
- Hematology
- Metabolic Disorders
Background:
- Elevated coagulation factor VII (FVII) is a potential risk factor for arterial thrombosis in coronary heart disease.
- The precise role of FVII and its interplay with lipids like cholesterol and triglycerides require further investigation.
Purpose of the Study:
- To investigate the correlation between FVII synthesis/activation and plasma lipid concentrations.
- To clarify the relationship between FVII levels and hyperlipidemia subtypes.
Main Methods:
- Assayed plasma levels of FVII antigen (FVII:ag) and FVII coagulant activity (FVIIc) in hyperlipidemic patients (types IIa, IIb, IV) and controls.
- Measured cholesterol, triglycerides, HDL, apolipoprotein B, and D-dimers.
- Assessed FVII activation state (FVIIa) via FVIIc/FVII:ag ratio.
Main Results:
- A significant correlation was observed between FVIIc and FVII:ag (r = 0.704; p < 0.01).
- Mean FVIIc and FVII:ag levels were significantly higher in type IV hyperlipidemia compared to controls and other types.
- FVIIc and FVII:ag showed a significant correlation with triglyceride levels.
Conclusions:
- FVII levels are elevated in type IV hyperlipidemia and correlate with triglyceride concentrations.
- No evidence of FVII activation was detected in the studied hyperlipidemic patients.
- The findings suggest a link between lipid metabolism and FVII levels, potentially impacting thrombosis risk.
Abstract:
There is evidence that the increase in coagulation factor VII (FVII) represents a predictive risk factor of arterial thrombosis in coronary heart disease. Its relative contribution to this multifactorial process and its relationship to other risk factors, namely cholesterol and triglycerides, is yet a matter of investigation. In this study we aimed to clarify whether FVII synthesis or activation correlated with plasma lipid concentrations. For this, we assayed the plasma levels of FVII antigen (FVII:ag) and FVII coagulant activity (FVIIc) in types IIa, IIb and IV hyperlipidemic individuals, together with the levels of cholesterol, triglycerides, high-density lipoproteins and apolipoprotein B. FVII activation state (FVIIa) was then assessed by FVIIc/FVII:ag. In order to assess the possible correlation of FVII levels with the generation of thrombin and formation of fibrin, we also assayed the plasma concentration of fibrin degradation products (D-dimers) in these patients. Considering all the patients studied, there was a fair correlation between FVIIc and FVII:ag (r = 0.704; p less than 0.01). The mean levels of FVIIc and FVII:ag were significantly higher in type IV hyperlipidemia than in controls (t = 4.260; p less than 0.001 and t = 3.015; p less than 0.01, respectively) and other types of hyperlipidemia. We also found that FVIIc and FVII:ag significantly correlated to triglyceride concentration. We could not detect an evident activation of FVII in these patients since FVIIc/FVII:ag was not elevated in comparison with controls, nor did it correlate with any of the lipid determinations in any of the types of hyperlipidemia studied.(ABSTRACT TRUNCATED AT 250 WORDS)